North Carolina Emerges as Global Bioscience Hub with $2.5B International Investment Surge
Key Insights
North Carolina has attracted 71 international life science companies from 20 countries, generating over $2.5 billion in investments and creating 17,000 jobs in the past five years.
Novo Nordisk leads the expansion with a historic $1.8 billion manufacturing facility in Clayton, representing the largest single manufacturing investment in North Carolina's history.
Major international companies including Aurobindo Pharma, Grifols, and FUJIFILM Diosynth (search) have established or expanded operations, drawn by the state's research infrastructure, skilled workforce, and strategic location.
North Carolina has solidified its position as a premier global bioscience hub, with a remarkable influx of international life science companies establishing and expanding operations across the state. Over the past five years, 71 companies from 20 countries have invested more than $2.5 billion in the region, creating a robust ecosystem that now employs over 17,000 professionals.
Major International Investments Transform Landscape
Danish pharmaceutical giant Novo Nordisk has made headlines with its unprecedented $1.8 billion investment in Clayton, North Carolina. The expansion, spanning an area equivalent to seven football fields, will create 700 high-paying jobs focused on diabetes (search) medicine production, marking the largest manufacturing investment in state history.
Other significant developments include India-based Aurobindo Pharma's $31.7 million investment in a new U.S. headquarters in Durham, promising 275 new R&D and pharmaceutical manufacturing positions. Spain's Grifols has committed $210 million to expand its Clayton campus with two new facilities for blood-derived therapeutics production.
Diverse Industry Representation
The international presence spans multiple sectors within the life sciences industry. FUJIFILM Diosynth (search) Biotechnologies, a Japanese contract manufacturing organization, has opened a 62,000-square-foot bioprocess R&D facility in Morrisville. Meanwhile, Australia's Mayne Pharma has announced a $65 million expansion of its Greenville campus, adding 110 new jobs.
Strategic Advantages Driving Growth
North Carolina's appeal to international companies stems from several key factors. The state offers proximity to major research universities and Research Triangle Park (search), the world's largest planned innovation park. Companies benefit from access to a highly educated workforce and sophisticated biomanufacturing training programs.
The state's central location along America's East Coast provides strategic advantages, including shorter flights to Europe compared to West Coast locations. This geographical benefit, combined with North Carolina's second-ranked business environment according to Site Selection magazine, has proven particularly attractive to European companies.
Infrastructure and Support Systems
The state's long-term investment in bioscience development has created a robust infrastructure supporting industry growth. The North Carolina Biotechnology Center (search), a state-funded non-profit organization, plays a crucial role in facilitating life science economic development and supporting incoming companies.
Recent additions to the state's bioscience landscape include Premier Research's planned $4.1 million operations center in Research Triangle Park (search), which will create 260 high-paying jobs, and Raumedic's $27 million development and production facility in Mills River for medical and pharmaceutical components.